|
Display Options:
|
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Beta-2 adrenergic receptor agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Heart Failure; Asthma; Pulmonary Disease, Chronic Obstructive; Lung Diseases, Obstructive
FENOTEROL
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 22M9P70OQ9 |
| Molecule Type: Small molecule |
| Molecular Formula: C17H21NO4 |
| Molecular Weight: 303.36 |
| AlogP: 2.06 |
| PSA: 92.95 |
| HBD: 5.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Opioid receptors; mu/kappa/delta agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Pain
DEXTROMORAMIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 9S4S6CIY83 |
| Molecule Type: Small molecule |
| Molecular Formula: C25H32N2O2 |
| Molecular Weight: 392.54 |
| AlogP: 3.71 |
| PSA: 32.78 |
| HBD: 0.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Alcohol dehydrogenase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
NITREFAZOLE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: VFD629099M |
| Molecule Type: Small molecule |
| Molecular Formula: C10H8N4O4 |
| Molecular Weight: 248.2 |
| AlogP: 2.0 |
| PSA: 104.1 |
| HBD: 0.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Carbonic anhydrase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Sleep Apnea, Obstructive; Epilepsy
SULTHIAME
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: I00Q766CZ2 |
| Molecule Type: Small molecule |
| Molecular Formula: C10H14N2O4S2 |
| Molecular Weight: 290.37 |
| AlogP: 0.26 |
| PSA: 97.54 |
| HBD: 1.0 |
| HBA: |
| #RotB: 2.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
3,3',4',5-TETRACHLOROSALICYLANILIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: HNE676755I |
| Molecule Type: Small molecule |
| Molecular Formula: C13H7Cl4NO2 |
| Molecular Weight: 351.02 |
| AlogP: 5.26 |
| PSA: 49.33 |
| HBD: 2.0 |
| HBA: |
| #RotB: 2.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
AMMONIUM BENZOATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: AC80WD7GPF |
| Molecule Type: Small molecule |
| Molecular Formula: C7H9NO2 |
| Molecular Weight: 139.15 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Lung Diseases, Obstructive
OXITROPIUM BROMIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: SF4NW7NH7C |
| Molecule Type: Small molecule |
| Molecular Formula: C19H26BrNO4 |
| Molecular Weight: 412.32 |
| AlogP: 1.45 |
| PSA: 59.06 |
| HBD: 1.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: NEUROLOGY DRUGS & NERVOUS SYSTEM; OTHER; PHARMACOLOGY
THERAPEUTIC INDICATION: Cough; Severe Acute Respiratory Syndrome; Stomatitis; Hepatolenticular Degeneration; Pneumonia; Exanthema; Hepatolenticular Degeneration
ZINC ACETATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: FM5526K07A |
| Molecule Type: Small molecule |
| Molecular Formula: C4H6O4Zn |
| Molecular Weight: 183.48 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Diabetes Mellitus
GLIQUIDONE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: C7C2QDD75P |
| Molecule Type: Small molecule |
| Molecular Formula: C27H33N3O6S |
| Molecular Weight: 527.64 |
| AlogP: 3.52 |
| PSA: 121.88 |
| HBD: 2.0 |
| HBA: |
| #RotB: 7.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Histamine H1 receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hypersensitivity
MIZOLASTINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 244O1F90NA |
| Molecule Type: Small molecule |
| Molecular Formula: C24H25FN6O |
| Molecular Weight: 432.5 |
| AlogP: 3.41 |
| PSA: 70.05 |
| HBD: 1.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
DITHIAZANINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 5L7E7IY5EH |
| Molecule Type: Small molecule |
| Molecular Formula: C23H23N2S2+ |
| Molecular Weight: 391.59 |
| AlogP: 6.25 |
| PSA: 7.12 |
| HBD: 0.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Glioblastoma; Neoplasm Metastasis; Asperger Syndrome; Autistic Disorder; Carcinoma, Neuroendocrine; Child Development Disorders, Pervasive; Esophageal Neoplasms; Neoplasms; Osteosarcoma; Uterine Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Depressive Disorder; Down Syndrome; Neuroendocrine Tumors; Pancreatic Neoplasms; Rectal Neoplasms; Schizophrenia; Stomach Neoplasms
FOLINIC ACID
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: Q573I9DVLP |
| Molecule Type: Small molecule |
| Molecular Formula: C20H23N7O7 |
| Molecular Weight: 473.45 |
| AlogP: -0.73 |
| PSA: 219.84 |
| HBD: 7.0 |
| HBA: |
| #RotB: 10.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cyclooxygenase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Chronic Pain; Gastroenteritis; Migraine Disorders; Sepsis; Fever; Pain
DIPYRONE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 934T64RMNJ |
| Molecule Type: Small molecule |
| Molecular Formula: C13H17N3O4S |
| Molecular Weight: 311.36 |
| AlogP: 0.77 |
| PSA: 84.54 |
| HBD: 1.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
QUININE BISULFATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: M201HC068W |
| Molecule Type: Small molecule |
| Molecular Formula: C20H28N2O10S2 |
| Molecular Weight: 520.58 |
| AlogP: 3.17 |
| PSA: 45.59 |
| HBD: 1.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Epilepsy
BECLAMIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: F5N0ALI65V |
| Molecule Type: Small molecule |
| Molecular Formula: C10H12ClNO |
| Molecular Weight: 197.66 |
| AlogP: 1.93 |
| PSA: 29.1 |
| HBD: 1.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hypoglycemia; Melanoma; Non-alcoholic Fatty Liver Disease; Obesity
FRUCTOSE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: B986VTP17J |
| Molecule Type: Small molecule |
| Molecular Formula: C6H12O6 |
| Molecular Weight: 180.16 |
| AlogP: -3.22 |
| PSA: 110.38 |
| HBD: 5.0 |
| HBA: |
| #RotB: 2.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MEPARFYNOL
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: B017BC5B1N |
| Molecule Type: Small molecule |
| Molecular Formula: C6H10O |
| Molecular Weight: 98.14 |
| AlogP: 0.78 |
| PSA: 20.23 |
| HBD: 1.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: INJECTION
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
AMMONIUM CHLORIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 01Q9PC255D |
| Molecule Type: Small molecule |
| Molecular Formula: H4ClN |
| Molecular Weight: 53.49 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
CHLORMERODRIN HG 197
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 1D6EFC579A |
| Molecule Type: Small molecule |
| Molecular Formula: C5H11ClHgN2O2 |
| Molecular Weight: 363.58 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
PIRBUTEROL HYDROCHLORIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: J6793T658K |
| Molecule Type: Small molecule |
| Molecular Formula: C12H22Cl2N2O3 |
| Molecular Weight: 313.23 |
| AlogP: 0.7 |
| PSA: 85.61 |
| HBD: 4.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Cardiovascular Diseases
PIRETANIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: DQ6KK6GV93 |
| Molecule Type: Small molecule |
| Molecular Formula: C17H18N2O5S |
| Molecular Weight: 362.41 |
| AlogP: 2.42 |
| PSA: 109.93 |
| HBD: 2.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
FORMALDEHYDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 1HG84L3525 |
| Molecule Type: Small molecule |
| Molecular Formula: CH2O |
| Molecular Weight: 30.03 |
| AlogP: -0.18 |
| PSA: 17.07 |
| HBD: 0.0 |
| HBA: |
| #RotB: 0.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Lung Diseases, Obstructive
METHOXYPHENAMINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: J3Z5SRI26Z |
| Molecule Type: Small molecule |
| Molecular Formula: C11H17NO |
| Molecular Weight: 179.26 |
| AlogP: 1.85 |
| PSA: 21.26 |
| HBD: 1.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Tobacco Use Disorder; Depressive Disorder; Phobia, Social
YOHIMBINE HYDROCHLORIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: NB2E1YP49F |
| Molecule Type: Small molecule |
| Molecular Formula: C21H27ClN2O3 |
| Molecular Weight: 390.91 |
| AlogP: 2.65 |
| PSA: 65.56 |
| HBD: 2.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
BEPHENIUM HYDROXYNAPHTHOATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 47RU9546DX |
| Molecule Type: Small molecule |
| Molecular Formula: C28H29NO4 |
| Molecular Weight: 443.54 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Respiratory Tract Diseases
ETHAMIVAN
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: M44O63YPV9 |
| Molecule Type: Small molecule |
| Molecular Formula: C12H17NO3 |
| Molecular Weight: 223.27 |
| AlogP: 1.88 |
| PSA: 49.77 |
| HBD: 1.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
CALCIUM GLUBIONATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 93H20IU3DN |
| Molecule Type: Small molecule |
| Molecular Formula: C18H34CaO20 |
| Molecular Weight: 610.53 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
HYDROTALCITE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 17432CG1KU |
| Molecule Type: Small molecule |
| Molecular Formula: CH16Al2Mg6O19 |
| Molecular Weight: 531.91 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
COBALTOUS CHLORIDE CO 57
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: ZL40NE83QQ |
| Molecule Type: Small molecule |
| Molecular Formula: Cl2Co |
| Molecular Weight: 127.84 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hyperthyroidism; Thyroid Neoplasms
SODIUM IODIDE I 131
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 29VCO8ACHH |
| Molecule Type: Small molecule |
| Molecular Formula: INa |
| Molecular Weight: 153.9 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Acute Kidney Injury; Neoplasms; Pain; Thromboembolism; Arthralgia; Myalgia
FELBINAC
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 94WNJ5U8L7 |
| Molecule Type: Small molecule |
| Molecular Formula: C14H12O2 |
| Molecular Weight: 212.25 |
| AlogP: 2.98 |
| PSA: 37.3 |
| HBD: 1.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Supplement
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
FERROUS GLUCONATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: U1B11I423Z |
| Molecule Type: Small molecule |
| Molecular Formula: C12H24FeO15 |
| Molecular Weight: 464.15 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
DEBRISOQUIN SULFATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: Q94064N9NW |
| Molecule Type: Small molecule |
| Molecular Formula: C20H28N6O4S |
| Molecular Weight: 448.55 |
| AlogP: 0.94 |
| PSA: 53.11 |
| HBD: 2.0 |
| HBA: |
| #RotB: 0.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
POTASSIUM SODIUM TARTRATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: QH257BPV3J |
| Molecule Type: Small molecule |
| Molecular Formula: C4H12KNaO10 |
| Molecular Weight: 282.22 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |